Who Generates More Revenue? Regeneron Pharmaceuticals, Inc. or Bausch Health Companies Inc.

Regeneron outpaces Bausch Health in revenue growth over a decade.

__timestampBausch Health Companies Inc.Regeneron Pharmaceuticals, Inc.
Wednesday, January 1, 201482635000002819557000
Thursday, January 1, 2015104988000004103728000
Friday, January 1, 201696740000004860427000
Sunday, January 1, 201787240000005872227000
Monday, January 1, 201883800000006710800000
Tuesday, January 1, 201986010000007863400000
Wednesday, January 1, 202080270000008497100000
Friday, January 1, 2021843400000016071700000
Saturday, January 1, 2022812400000012172900000
Sunday, January 1, 2023875700000013117200000
Monday, January 1, 202414202000000
Loading chart...

Unlocking the unknown

Revenue Race: Regeneron vs. Bausch Health

In the competitive landscape of pharmaceuticals, revenue generation is a key indicator of success. Over the past decade, Regeneron Pharmaceuticals, Inc. and Bausch Health Companies Inc. have been at the forefront of this race. From 2014 to 2023, Regeneron has shown a remarkable growth trajectory, with its revenue increasing by over 365%, peaking at approximately $13.1 billion in 2023. In contrast, Bausch Health's revenue has remained relatively stable, with a slight decline from its 2015 peak of around $10.5 billion to $8.8 billion in 2023. This trend highlights Regeneron's dynamic growth strategy and its ability to capture market share, while Bausch Health maintains a steady course. As the pharmaceutical industry continues to evolve, these revenue trends offer valuable insights into the strategic directions of these two giants.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025